[Clinical studies of cefoxitin in the pediatric field (author's transl)].
1. The in vitro antibacterial activity of cefoxitin was nearly equal to that of CEZ and CET against the 6 species of clinically isolated strains. Cefoxitin, furthermore, had an antibacterial activity against the strains of P. morganii resistant to CEZ and CET. 2. Cefoxitin was applied to a total of 17 patients including 6 cases of bronchitis, 5 of pneumonia, 2 of enteritis, and 1 each of pharyngitis, laryngitis, sinusitis and lymphadenitis. The results showed an efficacy rate of 88%. In the 6 patients from whom the isolation of pathogenic organisms was possible, the bacteriological response to cefoxitin was appreciable the efficacy rate being 83%. Thus, it is considered that cefoxitin also has a significant antibacterial activity in vivo. 3. As to the side effects following the administration of cefoxitin, urticaria-like eruption was observed in 1 case, and an elevation of transaminase in another. These findings, however, became normal soon after discontinuation of cefoxitin treatment.
D000293:Adolescent; D000367:Age Factors; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy*; D002440:Cefoxitin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male
D002440:Cefoxitin